Trial Profile
Oregovomab and rintatolimod as adjuvant therapy for cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Oregovomab (Primary) ; Rintatolimod (Primary)
- Indications Cancer
- Focus Therapeutic Use
- 18 Apr 2011 New trial record